Mechanism of action
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase (IleRS), an enzyme essential for incorporating isoleucine into nascent bacterial proteins during translation. By blocking this aminoacyl-tRNA synthetase, mupirocin depletes charged isoleucyl-tRNA and halts bacterial protein synthesis, ultimately exerting bacteriostatic effects at low concentrations and bactericidal effects at higher concentrations achieved with topical application.
The drug shows minimal affinity for the mammalian eukaryotic isoleucyl-tRNA synthetase, accounting for its selective toxicity and excellent safety profile. This unique target means mupirocin has no cross-resistance with other classes of antibiotics such as beta-lactams, aminoglycosides, fluoroquinolones, or macrolides. It demonstrates potent activity against gram-positive cocci, particularly Staphylococcus aureus (including methicillin-resistant strains, MRSA) and Streptococcus pyogenes, which are the most common causative organisms in superficial skin infections.
Mupirocin is available in two formulations: a 2% ointment in a polyethylene glycol (PEG) base for general dermatologic use, and a 2% ointment in a paraffin (petroleum jelly) base specifically for intranasal application. The paraffin base is preferred for nasal mucosa because PEG can be absorbed systemically from mucosal surfaces and has been associated with renal toxicity in patients with compromised renal function.
- Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis selectively in bacteria.
- First-line topical treatment for impetigo caused by S. aureus and S. pyogenes.
- Intranasal mupirocin (paraffin base) eradicates MRSA nasal colonization and reduces surgical site infections.
- Minimal systemic absorption; negligible drug interactions and safe in pregnancy.
- Polyethylene glycol (PEG) vehicle in dermatologic ointment can cause renal toxicity if absorbed; avoid in renal impairment on large areas.
- Prolonged or inappropriate use can select for high-level mupirocin resistance (plasmid-mediated mupA gene).
- Not for ophthalmic use or systemic infections; strictly a topical agent.
- Standard treatment duration follows the product label for both impetigo and nasal MRSA decolonization.
Indications
Mupirocin is indicated for:
- Impetigo: Primary treatment for localized impetigo caused by S. aureus or S. pyogenes. It is often first-line for small areas of non-bullous impetigo, avoiding systemic antibiotics.
- Nasal MRSA decolonization: Intranasal mupirocin (paraffin base) is used to eradicate nasal carriage of MRSA in patients undergoing elective surgery (especially orthopedic and cardiac procedures), healthcare workers, and patients with recurrent MRSA skin and soft tissue infections. Decolonization reduces the risk of postoperative MRSA infections.
- Secondary infected traumatic skin lesions: Small lacerations, abrasions, or sutured wounds with secondary bacterial infection limited in size (area ≤100 cm² or length ≤10 cm).
Mupirocin is not appropriate for widespread or deep skin infections, which require systemic antibiotics. It should not be applied to mucosal surfaces other than the nasal mucosa (the paraffin formulation only), and is not indicated for ophthalmic use.
Pharmacokinetics
Mupirocin is intended for topical use and exhibits minimal systemic absorption through intact skin. When applied to damaged skin or large body surface areas, small amounts may be absorbed, but plasma concentrations remain negligible.
Metabolism and elimination: Any systemically absorbed mupirocin is rapidly metabolized in the skin and liver to monic acid, an inactive metabolite. Monic acid is then excreted renally. The short half-life and rapid metabolism result in no systemic accumulation with repeated topical application.
Formulation considerations: The polyethylene glycol (PEG) vehicle used in the dermatologic ointment can be absorbed from damaged skin or mucous membranes. In patients with moderate to severe renal impairment or extensive application to denuded areas, absorbed PEG may accumulate and cause toxicity. The intranasal formulation uses a paraffin base to avoid this risk.
Because systemic absorption is minimal, mupirocin does not interact with hepatic cytochrome P450 enzymes and does not require dose adjustment for hepatic or renal impairment when used topically as directed.
Adverse effects
Mupirocin is generally well tolerated. Most adverse effects are local and mild.
Common
- Local irritation: Burning, stinging, itching, or pain at the application site (1–2% of patients)
- Contact dermatitis: Allergic or irritant contact dermatitis, erythema, rash, dry skin
Uncommon
- Nasal application: Rhinitis, nasal dryness, epistaxis, pharyngitis, altered taste, headache
- Fungal superinfection: Prolonged or repeated use may lead to overgrowth of non-susceptible organisms, including fungi (Candida)
Rare
- Systemic absorption toxicity (with PEG formulation on large denuded areas or mucous membranes): Renal impairment from absorbed polyethylene glycol, particularly in patients with pre-existing renal dysfunction. This is why the paraffin-based formulation is used intranasally.
- Hypersensitivity reactions: Angioedema, anaphylaxis (extremely rare)
Resistance: Prolonged or inappropriate use of mupirocin can select for resistant strains of S. aureus. High-level resistance (MIC >512 mg/L) is mediated by an acquired plasmid-borne isoleucyl-tRNA synthetase gene (mupA/ileS-2) and renders mupirocin clinically ineffective. Low-level resistance (MIC 8–256 mg/L) results from point mutations in the native chromosomal ileS gene. To minimize resistance, mupirocin should be reserved for appropriate indications and used for short courses.
Contraindications and warnings
Contraindications
- Hypersensitivity: Known hypersensitivity to mupirocin or any component of the formulation (polyethylene glycol or paraffin base)
- Ophthalmic use: Not for use in the eyes; can cause severe irritation
Warnings and precautions
- Renal impairment: The polyethylene glycol (PEG) vehicle in the dermatologic ointment may be absorbed and accumulate in patients with moderate to severe renal dysfunction, especially when applied to large surface areas or mucosal surfaces. Use the paraffin-based intranasal formulation for nasal application. Avoid extensive application of the PEG formulation in patients with impaired renal function.
- Prolonged use: Extended or repeated courses may promote overgrowth of non-susceptible organisms (bacterial or fungal superinfection) and select for mupirocin-resistant S. aureus. Limit duration to the shortest effective course.
- Not for systemic infections: Mupirocin is a topical agent only. Do not use for pneumonia, deep tissue infections, or systemic infections.
- Avoid mucous membranes (except intranasal paraffin formulation): The PEG-based ointment should not be applied to nasal mucosa or other mucous membranes.
Pregnancy and lactation
- Pregnancy: Systemic absorption is negligible with topical application. Generally considered safe in pregnancy when used as directed. No adequate well-controlled studies exist, but risk is expected to be minimal.
- Lactation: Minimal systemic absorption suggests low risk to the nursing infant. Compatible with breastfeeding when applied to small areas and not on the breast.
Drug interactions
Mupirocin has minimal systemic absorption and no known clinically significant drug-drug interactions when used topically as directed. Because it does not enter systemic circulation in meaningful amounts, it does not interact with hepatic or renal drug metabolism pathways.
Considerations:
- Other topical agents: Avoid concurrent application of other topical products to the same area, as this may dilute mupirocin or alter absorption. If multiple topical agents are necessary, separate application times.
- Chloramphenicol: In vitro and theoretical concerns exist that chloramphenicol (also a protein synthesis inhibitor) might antagonize mupirocin activity, but this is not clinically established and both are rarely used concurrently.
No dose adjustments or monitoring are required for drug interactions with mupirocin.
Clinical pearls
- Classic boards association: Mupirocin is the go-to topical antibiotic for impetigo and nasal MRSA decolonization in USMLE vignettes. If a question describes a child with honey-crusted lesions on the face and asks for topical therapy, mupirocin is the answer.
- Unique mechanism: Mupirocin's inhibition of isoleucyl-tRNA synthetase is a high-yield fact. It is structurally unrelated to any other antibiotic class, so cross-resistance is uncommon—making it valuable for MRSA.
- Resistance patterns: Recognize that mupirocin resistance (especially high-level, plasmid-mediated) is an emerging problem in some institutions with heavy mupirocin use. Reserve it for appropriate indications and short courses to preserve efficacy.
- Formulation matters: The paraffin-based intranasal ointment is used for MRSA decolonization (applied intranasally to each nostril according to the product label). The PEG-based dermatologic ointment is for skin infections but should not be used on mucous membranes or in renally impaired patients on large areas.
- Not for eyes: Emphasize that mupirocin is never used ophthalmically. If a vignette involves ocular infection, mupirocin is incorrect.
- Duration: Standard treatment courses follow the product label for impetigo and nasal decolonization. Reassess if no improvement within the expected timeframe.
- Cost and availability: Mupirocin is available generically and is relatively affordable, making it accessible for outpatient treatment of superficial infections.
- Comparing to alternatives: For impetigo, mupirocin is often compared to retapamulin (another topical antibiotic) and oral agents like cephalexin or dicloxacillin. Mupirocin is preferred for localized disease to avoid systemic antibiotic exposure. For MRSA decolonization, chlorhexidine body washes are often used adjunctively with intranasal mupirocin.
MURSA for Mupirocin uses: MRSA nasal decolonization, Utopian for impetigo, Reserve for topical use, Synthetase (isoleucyl-tRNA) inhibitor, Avoid in eyes.
Practice questions
1. A 6-year-old boy is brought to the pediatrician with multiple honey-colored crusted lesions on his face that began 3 days ago after a minor abrasion. Physical examination reveals small vesicles and pustules with surrounding erythema on the cheeks and around the nose. The lesions are non-painful and there is no fever. Which of the following is the most appropriate initial treatment?
2. A 55-year-old man with a history of recurrent MRSA skin abscesses is scheduled for elective total hip arthroplasty in 2 weeks. Nasal swab culture is positive for MRSA. To reduce his risk of postoperative surgical site infection, which of the following interventions is most appropriate?
3. A 34-year-old woman with chronic kidney disease (creatinine clearance 25 mL/min) presents with a small infected laceration on her forearm. Culture grows methicillin-susceptible Staphylococcus aureus. The clinician considers topical mupirocin. Which of the following is the most important consideration in this patient?
Frequently asked questions
How does mupirocin work?
Mupirocin works by reversibly inhibiting bacterial isoleucyl-tRNA synthetase, an enzyme required to incorporate isoleucine into bacterial proteins during translation. This blocks bacterial protein synthesis, leading to bacteriostatic or bactericidal effects depending on concentration. Because it targets a unique enzyme not affected by other antibiotic classes, mupirocin has minimal cross-resistance and is highly effective against gram-positive cocci, especially Staphylococcus aureus (including MRSA) and Streptococcus pyogenes.
What are the side effects of mupirocin?
Mupirocin side effects are typically mild and localized to the application site. Common reactions include burning, stinging, itching, and contact dermatitis. When used intranasally, it may cause nasal dryness, rhinitis, or altered taste. Systemic absorption is minimal, but the polyethylene glycol vehicle in the dermatologic formulation can rarely cause renal toxicity if applied to large denuded areas in patients with kidney impairment. Prolonged use can lead to fungal superinfection or development of bacterial resistance.
What is mupirocin used for?
Mupirocin is used topically to treat impetigo and other small secondary infected skin lesions caused by Staphylococcus aureus or Streptococcus pyogenes. The intranasal formulation is used to eradicate nasal colonization of methicillin-resistant S. aureus (MRSA) in patients prior to surgery or with recurrent MRSA infections. It is not suitable for deep or systemic infections and should only be applied to skin or nasal mucosa (with the appropriate formulation).
Can mupirocin be used for MRSA?
Yes, mupirocin is highly effective against MRSA. Intranasal mupirocin ointment (paraffin base) is specifically used to decolonize the nares of MRSA carriers, reducing the risk of postoperative infections and recurrent skin infections. It can also be used topically to treat MRSA skin infections such as impetigo or small infected wounds. However, prolonged or repeated use should be avoided to prevent selection of mupirocin-resistant MRSA strains, which are increasingly reported in some settings.
Mupirocin vs bacitracin — what is the difference?
Mupirocin inhibits bacterial isoleucyl-tRNA synthetase and has potent activity against Staphylococcus aureus (including MRSA) and Streptococcus pyogenes, making it the preferred agent for impetigo and MRSA decolonization. Bacitracin inhibits bacterial cell wall synthesis and has broader but weaker gram-positive coverage; it is commonly used for minor cuts and abrasions but is less effective for established impetigo and has no activity against MRSA. Bacitracin is available over-the-counter, while mupirocin requires a prescription. Mupirocin is more targeted and potent for the specific infections it treats.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: D06AX09WHO ATC/DDD index: R01AX06
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.